Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

Primrose, J; Falk, S; Finch-Jones, M; Valle, Juan W; O'Reilly, D; Siriwardena, A; Hornbuckle, J; Peterson, M; Rees, M; Iveson, T; Hickish, T; Butler, R; Stanton, L; Dixon, E; Little, L; Bowers, M; Pugh, S; Garden, O; Cunningham, D; Maughan, T; Bridgewater, J

Affiliation

The University of Southampton, Southampton, UK. Electronic address: j.n.primrose@soton.ac.uk

Issue Date

2014-04-04

Metadata

Show full item record

Abstract

Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colorectal liver metastasis.

Citation

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. 2014: Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/315913

DOI

10.1016/S1470-2045(14)70105-6

PubMed ID

24717919

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications